Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yakangling is a fixed-dose combination pharmaceutical product primarily utilized in dental medicine for the treatment of oral infections caused by anaerobic bacteria. It consists of metronidazole, a nitroimidazole antibiotic, and vitamin B6 (pyridoxine). Metronidazole functions as a prodrug that is selectively reduced within anaerobic microorganisms; its reduced form generates reactive intermediates that cause DNA strand breakage and inhibit nucleic acid synthesis, ultimately leading to bacterial cell death. Vitamin B6 is incorporated into the formulation to mitigate common adverse effects associated with metronidazole therapy, such as gastrointestinal distress and potential peripheral neuropathy. Yakangling is widely indicated for conditions including periodontitis, gingivitis, and pericoronitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yakangling.